Гипогликемии как основной фактор выбора целей гликемического контроля и тактики лечения больных сахарным диабетом типа 2

1. Morrish NJ, Wang SL, Stevens LK et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl. 2): 14–21.
2. Gore MO, McGuire DK. The 10-year posttrial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diab Vasc Dis Res 2009; 6: 53–5.
3. Desouza C, Bolli G, Fonseca V. Hypoglycemia, Diabetes, and Cardiovascular Events. Diabetes Care 2010; 33: 1389–94.
4. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008; 25: 245–54.
5. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 5-е изд. Под ред. И.И.Дедова, М.В.Шестаковой. М., 2011.
6. Murad MH, Coto-Yglesias F, Wang AT et al. Clinical review: Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009; 94: 741.
7. Аметов А.С., Иванова Е.В. Гипогликемия. Сахарный диабет 2 типа. Проблемы и решения. М.: ГЭОТАР- Медиа, 2011: 115–43.
8. Miller DR, Finckel G, Lafrance JP et al. Hypoglycaemia and risk of myocardial infarction in U.S. veterans with Diabetes. EASD 2009. Diabetologia 2009; 52 (Suppl. 1): 63.
9. Alvarez GF, Tofe PS, Krishnarajah G et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAPDM) Study. Diabetes Obes Metab 2008; 10 (Suppl. 1): 25–32.
10. Zoungas S, Patel A, Chalmers J et al. Severe Hypoglycemia and Risks of Vascular Events and Death. N Engl J Med 363; 15 okt 7, 2010.
11. Zoungas S, Turnbull F. Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials? Evid Based Med 2012; 17 (3): 98–9. Epub 2011 Nov 28.
12. Dejager S, Schweizer A. Minimizing the risk of hypoglycemia with Vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diab ther 2011; 2 (2): 51–66.
13. Анциферов М.Б., Дорофеева Л.Г. Вилдаглиптин – новый препарат из класса ингибиторов дипептидилпептидазы-4 для лечения сахарного диабета типа 2. Новые лекарственные средства и технологии. Фарматека, 2009; 3.
14. Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30–5.
15. Scherbaum WA, Schweizer A, Mari A et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008; 10: 675–82.
16. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132–8.
17. Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy ofvildagliptin. Diabetes Ther 2012; 3 (1): 8. Epub 2012 Jun 27.
18. Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. Практическое руководство для врачей. М., 2010.
19. Kothny W, Shao Q, Groop P-H, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012; 14 (11): 1032–9.
20. Blüher M, Kurz I, Dannenmaier S, Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes 2012; Vol. 15; 3 (9): 161–9.
21. Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009; 63: 1446–50.
22. Garber AJ, Schweizer A, Baron MA et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166–74.
23. Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; 10: 1047–56.
24 .Kikuchi M, Haneda M, Koya D et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 89: 216–23.
25. Fonseca V, Schweizer A, Albrecht D et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148–55.

Ю.Ш.Халимов, В.В.Салухов, Е.О.Улупова 

Кафедра военно-полевой терапии ФГКВОУ ВПО Военно-медицинская академия им.С.М.Кирова, Санкт-Петербург